Evidence-Based Medicine Guidelines
Anti-angiogenic therapies for metastatic colorectal cancer
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Anti-angiogenic Therapies for Metastatic Colorectal Cancer." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/452952/all/Anti_angiogenic_therapies_for_metastatic_colorectal_cancer.
Anti-angiogenic therapies for metastatic colorectal cancer. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. https://evidence.unboundmedicine.com/evidence/view/EBMG/452952/all/Anti_angiogenic_therapies_for_metastatic_colorectal_cancer. Accessed September 22, 2023.
Anti-angiogenic therapies for metastatic colorectal cancer. (2019). In Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited. https://evidence.unboundmedicine.com/evidence/view/EBMG/452952/all/Anti_angiogenic_therapies_for_metastatic_colorectal_cancer
Anti-angiogenic Therapies for Metastatic Colorectal Cancer [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. [cited 2023 September 22]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/452952/all/Anti_angiogenic_therapies_for_metastatic_colorectal_cancer.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Anti-angiogenic therapies for metastatic colorectal cancer
ID - 452952
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/452952/all/Anti_angiogenic_therapies_for_metastatic_colorectal_cancer
PB - Duodecim Medical Publications Limited
DB - Evidence Central
DP - Unbound Medicine
ER -
